L 136/72

EN

Official Journal of the European Union
ANNEX I

GENERAL PROVISIONS FOR ASSESSING SUBSTANCES AND PREPARING CHEMICAL SAFETY REPORTS
0.

INTRODUCTION

0.1.

The purpose of this Annex is to set out how manufacturers and importers are to assess and document that therisks arising from the substance they manufacture or import are adequately controlled during manufacture andtheir own use(s) and that others further down the supply chain can adequately control the risks. This Annex shallalso apply adapted as necessary to producers and importers of articles required to make a chemical safety assessment as part of a registration.

0.2.

The chemical safety assessment shall be prepared by one or more competent person(s) who have appropriate
experience and received appropriate training, including refresher training.

0.3.

The chemical safety assessment of a manufacturer shall address the manufacture of a substance and all the identified uses. The chemical safety assessment of an importer shall address all identified uses. The chemical safety assessment shall consider the use of the substance on its own (including any major impurities and additives), in a
preparation and in an article, as defined by the identified uses. The assessment shall consider all stages of the lifecycle of the substance resulting from the manufacture and identified uses. The chemical safety assessment shall bebased on a comparison of the potential adverse effects of a substance with the known or reasonably foreseeable
exposure of man and/or the environment to that substance taking into account implemented and recommended
risk management measures and operational conditions.

0.4.

Substances whose physicochemical, toxicological and ecotoxicological properties are likely to be similar or follow a
regular pattern as a result of structural similarity may be considered as a group, or ‘category’ of substances. If the
manufacturer or importer considers that the chemical safety assessment carried out for one substance is sufficient
to assess and document that the risks arising from another substance or from a group or ‘category’ of substances
are adequately controlled then he can use that chemical safety assessment for the other substance or group or ‘category’ of substances. The manufacturer or importer shall provide a justification for this.

0.5.

The chemical safety assessment shall be based on the information on the substance contained in the technicaldossier and on other available and relevant information. Manufacturers or importers submitting a proposal for
testing in accordance with Annexes IX and X shall record this under the relevant heading of the chemical safety
report. Available information from assessments carried out under other international and national programmes
shall be included. Where available and appropriate, an assessment carried out under Community legislation (e.g.
risk assessments completed under Regulation (EEC) No 793/93) shall be taken into account in the development of,and reflected in, the chemical safety report. Deviations from such assessments shall be justified.

Thus the information to be considered includes information related to the hazards of the substance, the exposure
arising from the manufacture or import, the identified uses of the substance, operational conditions and risk
management measures applied or recommended to downstream users to be taken into account.

In accordance with section 3 of Annex XI in some cases, it may not be necessary to generate missing information,
because risk management measures and operational conditions which are necessary to control a well-characterised
risk may also be sufficient to control other potential risks, which will not therefore need to be characterised
precisely.

If the manufacturer or importer considers that further information is necessary for producing his chemical safety
report and that this information can only be obtained by performing tests in accordance with Annex IX or X, heshall submit a proposal for a testing strategy, explaining why he considers that additional information is necessary
and record this in the chemical safety report under the appropriate heading. While waiting for results of further
testing, he shall record in his chemical safety report, and include in the exposure scenario developed, the interim
risk management measures that he has put in place and those he recommends to downstream users intended to
manage the risks being explored.

0.6.

A chemical safety assessment performed by a manufacturer or an importer for a substance shall include thefollowing steps in accordance with the respective sections of this Annex:
1. Human health hazard assessment.
2. Human health hazard assessment of physicochemical properties.

29.5.200729.5.2007

EN

Official Journal of the European Union

3. Environmental hazard assessment.
4. PBT and vPvB assessment.
If as a result of steps 1 to 4 the manufacturer or importer concludes that the substance or the preparation meetsthe criteria for classification as dangerous according to Directive 67/548/EEC or Directive 1999/45/EC or isassessed to be a PBT or vPvB, the chemical safety assessment shall also consider the following steps:
5. Exposure assessment
5.1. The generation of exposure scenario(s) or the generation of relevant use and exposure categories if appropriate.
5.2. Exposure estimation.
6. Risk characterisation
A summary of all the relevant information used in addressing the points above, shall be presented under the relevant heading of the Chemical Safety Report (Section 7).

0.7.

The main element of the exposure part of the chemical safety report is the description of the exposure scenario(s)implemented for the manufacturer's production, the manufacturer or importer's own use, and those recommended
by the manufacturer or importer to be implemented for the identified use(s).

An exposure scenario is the set of conditions that describe how the substance is manufactured or used during its
life-cycle and how the manufacturer or importer controls, or recommends downstream users to control, exposuresof humans and the environment. These sets of conditions contain a description of both the risk management
measures and operational conditions which the manufacturer or importer has implemented or recommends to be
implemented by downstream users.

If the substance is placed on the market, the relevant exposure scenario(s), including the risk management measuresand operational conditions shall be included in an annex to the safety data sheet in accordance with Annex II.

0.8.

The level of detail required in describing an exposure scenario will vary substantially from case to case, dependingon the use of a substance, its hazardous properties and the amount of information available to the manufacturer
or importer. Exposure scenarios may describe the appropriate risk management measures for several individual
processes or uses of a substance. An exposure scenario may thereby cover a large range of processes or uses. Exposure scenarios covering a wide range of processes or uses may be referred to as Exposure Categories. Further
mention of Exposure Scenario in this Annex and Annex II includes Exposure Categories if they are developed.

0.9.

Where information is not necessary in accordance with Annex XI, this fact shall be stated under the appropriate
heading of the chemical safety report and a reference shall be made to the justification in the technical dossier. The
fact that no information is required shall also be stated in the safety data sheet.

0.10. In relation to particular effects, such as ozone depletion, photochemical ozone creation potential, strong odour andtainting, for which the procedures set out in Sections 1 to 6 are impracticable, the risks associated with such
effects shall be assessed on a case-by-case basis and the manufacturer or importer shall include a full description
and justification of such assessments in the chemical safety report and summarised in the safety data sheet.

0.11. When assessing the risk of the use of one or more substances incorporated into a special preparation (for instancealloys), the way the constituent substances are bonded in the chemical matrix shall be taken into account.

0.12. Where the methodology described in this Annex is not appropriate, details of alternative methodology used shallbe explained and justified in the chemical safety report.

L 136/73

L 136/74

EN

Official Journal of the European Union

0.13. Part A of the chemical safety report shall include a declaration that the risk management measures outlined in therelevant exposure scenarios for the manufacturer's or importer's own use(s) are implemented by the manufacturer
or importer and that those exposure scenarios for the identified uses are communicated to distributors and downstream users in the safety data sheet(s).

1.

HUMAN HEALTH HAZARD ASSESSMENT

1.0.

Introduction

1.0.1. The objective of the human health hazard assessment shall be:— to determine the classification and labelling of a substance in accordance with Directive 67/548/EEC, and— to derive levels of exposure to the substance above which humans should not be exposed. This level of exposure is known as the Derived No-Effect Level (DNEL).
1.0.2. The human health hazard assessment shall consider the toxicokinetic profile (i.e. absorption, metabolism, distribution and elimination) of the substance and the following groups of effects, (1) acute effects (acute toxicity, irritationand corrosivity), (2) sensitisation, (3) repeated dose toxicity and (4) CMR effects (carcinogenity, mutagenicity andtoxicity for reproduction). Based on all the available information, other effects shall be considered when necessary.
1.0.3. The hazard assessment shall comprise the following four steps:
Step 1: Evaluation of non-human information.
Step 2: Evaluation of human information.
Step 3: Classification and Labelling.
Step 4: Derivation of DNELs.
1.0.4. The first three steps shall be undertaken for every effect for which information is available and shall be recorded
under the relevant section of the Chemical Safety Report and where required and in accordance with Article 31,
summarised in the Safety Data Sheet under headings 2 and 11.
1.0.5. For any effect for which no relevant information is available, the relevant section shall contain the sentence: ‘This
information is not available’. The justification, including reference to any literature search carried out, shall be
included in the technical dossier.
1.0.6. Step 4 of the human health hazard assessment shall be undertaken by integrating the results from the first threesteps and shall be included under the relevant heading of the Chemical Safety Report and summarised in the Safety
Data Sheet under heading 8.1.

1.1.

Step 1: Evaluation of non-human information

1.1.1. The evaluation of non-human information shall comprise:— the hazard identification for the effect based on all available non-human information,— the establishment of the quantitative dose (concentration)-response (effect) relationship.
1.1.2. When it is not possible to establish the quantitative dose (concentration)-response (effect) relationship, then thisshould be justified and a semi-quantitative or qualitative analysis shall be included. For instance, for acute effects it
is usually not possible to establish the quantitative dose (concentration)-response (effect) relationship on the basisof the results of a test conducted in accordance with test methods laid down in a Commission Regulation as specified in Article 13(3). In such cases it suffices to determine whether and to which degree the substance has aninherent capacity to cause the effect.
1.1.3. All non-human information used to assess a particular effect on humans and to establish the dose (concentration)response (effect) relationship, shall be briefly presented, if possible in the form of a table or tables, distinguishing
between in vitro, in vivo and other information. The relevant test results (e.g. LD50, NO(A)EL or LO(A)EL) and test
conditions (e.g. test duration, route of administration) and other relevant information shall be presented, in internationally recognised units of measurement for that effect.

29.5.200729.5.2007

EN

Official Journal of the European Union

1.1.4. If one study is available then a robust study summary should be prepared for that study. If there are several studies
addressing the same effect, then, having taken into account possible variables (e.g. conduct, adequacy, relevance oftest species, quality of results, etc.), normally the study or studies giving rise to the highest concern shall be used toestablish the DNELs and a robust study summary shall be prepared for that study or studies and included as partof the technical dossier. Robust summaries will be required of all key data used in the hazard assessment. If thestudy or studies giving rise to the highest concern are not used, then this shall be fully justified and included aspart of the technical dossier, not only for the study being used but also for all studies demonstrating a higher
concern than the study being used. It is important irrespective of whether hazards have been identified or not thatthe validity of the study be considered.

1.2.

Step 2: Evaluation of human information
If no human information is available, this part shall contain the statement: ‘No human information is available’.
However, if human information is available, it shall be presented, if possible in the form of a table.

1.3.

Step 3: Classification and Labelling

1.3.1. The appropriate classification and labelling developed in accordance with the criteria in Directive 67/548/EEC shallbe presented and justified. Where applicable Specific Concentration limits, resulting from the application of
Article 4(4) of Directive 67/548/EEC and Articles 4 to 7 of Directive 1999/45/EC, shall be presented and, if they
are not included in Annex I to Directive 67/548/EEC, justified. The assessment should always include a statement
as to whether the substance fulfils or does not fulfil the criteria given in Directive 67/548/EEC for CMR, categories 1 and 2.
1.3.2. If the information is inadequate to decide whether a substance should be classified for a particular end-point, theregistrant shall indicate and justify the action or decision he has taken as a result.

1.4.

Step 4: Identification of DNEL(s)1.4.1. Based on the outcomes of steps 1 and 2, (a) DNEL(s) shall be established for the substance, reflecting the likely
route(s), duration and frequency of exposure. For some endpoints, especially mutagenicity and carcinogenicity, theavailable information may not enable a threshold, and therefore a DNEL, to be established. If justified by the exposure scenario(s), a single DNEL may be sufficient. However, taking into account the available information and theexposure scenario(s) in Section 9 of the Chemical Safety Report it may be necessary to identify different DNELs foreach relevant human population (e.g. workers, consumers and humans liable to exposure indirectly via the environment) and possibly for certain vulnerable sub-populations (e.g. children, pregnant women) and for different routesof exposure. A full justification shall be given specifying, inter alia, the choice of the information used, the route of
exposure (oral, dermal, inhalation) and the duration and frequency of exposure to the substance for which the
DNEL is valid. If more than one route of exposure is likely to occur, then a DNEL shall be established for eachroute of exposure and for the exposure from all routes combined. When establishing the DNEL, the following
factors shall, inter alia, be taken into account:(a) the uncertainty arising, among other factors, from the variability in the experimental information and fromintra- and inter-species variation;(b) the nature and severity of the effect;(c) the sensitivity of the human (sub-)population to which the quantitative and/or qualitative information on exposure applies.
1.4.2. If it is not possible to identify a DNEL, then this shall be clearly stated and fully justified.

2.

PHYSICOCHEMICAL HAZARD ASSESSMENT

2.1.

The objective of the hazard assessment for physicochemical properties shall be to determine the classification andlabelling of a substance in accordance with Directive 67/548/EEC.

2.2.

As a minimum, the potential effects to human health shall be assessed for the following physicochemical properties:— explosivity,— flammability,— oxidising potential.
If the information are inadequate to decide whether a substance should be classified for a particular end-point, theregistrant shall indicate and justify the action or decision he has taken as a result.

L 136/75

L 136/76

EN

Official Journal of the European Union

2.3.

The assessment of each effect shall be presented under the relevant heading of the Chemical Safety Report(Section 7) and where required and in accordance with Article 31, summarised in the Safety Data Sheet underheadings 2 and 9.

2.4.

For every physicochemical property, the assessment shall entail an evaluation of the inherent capacity of thesubstance to cause the effect resulting from the manufacture and identified uses.

2.5.

The appropriate classification and labelling developed in accordance with the criteria in Directive 67/548/EEC shallbe presented and justified.

3.

ENVIRONMENTAL HAZARD ASSESSMENT

3.0.

Introduction

3.0.1. The objective of the environmental hazard assessment shall be to determine the classification and labelling of a
substance in accordance with Directive 67/548/EEC and to identify the concentration of the substance below
which adverse effects in the environmental sphere of concern are not expected to occur. This concentration is
known as the Predicted No-Effect Concentration (PNEC).
3.0.2. The environmental hazard assessment shall consider the potential effects on the environment, comprising the(1) aquatic (including sediment), (2) terrestrial and (3) atmospheric compartments, including the potential effects
that may occur (4) via food-chain accumulation. In addition, the potential effects on the (5) microbiological activityof sewage treatment systems shall be considered. The assessment of the effects on each of these five environmental
spheres shall be presented under the relevant heading of the Chemical Safety Report (Section 7) and where required
and in accordance with Article 31, summarised in the Safety Data Sheet under headings 2 and 12.
3.0.3. For any environmental sphere, for which no effect information is available, the relevant section of the chemicalsafety report shall contain the sentence: ‘This information is not available’. The justification, including reference to
any literature research carried out, shall be included in the technical dossier. For any environmental sphere forwhich information is available, but the manufacturer or importer believes that it is not necessary to conduct thehazard assessment, the manufacturer or importer shall present a justification, with reference to pertinent information, under the relevant heading of the Chemical Safety Report (Section 7) and where required and in accordancewith Article 31, summarised in the Safety Data Sheet under heading 12.
3.0.4. The hazard assessment shall comprise the following three steps, which shall be clearly identified as such in theChemical Safety Report:
Step 1: Evaluation of information.
Step 2: Classification and Labelling.
Step 3: Derivation of the PNEC.

3.1.

Step 1: Evaluation of information

3.1.1. The evaluation of all available information shall comprise:— the hazard identification based on all available information,— the establishment of the quantitative dose (concentration)-response (effect) relationship.
3.1.2. When it is not possible to establish the quantitative dose (concentration)-response (effect) relationship, then thisshould be justified and a semi-quantitative or qualitative analysis shall be included.
3.1.3. All information used to assess the effects on a specific environmental sphere shall be briefly presented, if possible
in the form of a table or tables. The relevant test results (e.g. LC50 or NOEC) and test conditions (e.g. test duration,route of administration) and other relevant information shall be presented, in internationally recognised units ofmeasurement for that effect.

29.5.200729.5.2007

EN

Official Journal of the European Union

3.1.4. All information used to assess the environmental fate of the substance shall be briefly presented, if possible in theform of a table or tables. The relevant test results and test conditions and other relevant information shall bepresented, in internationally recognised units of measurement for that effect.
3.1.5. If one study is available then a robust study summary should be prepared for that study. Where there is more than
one study addressing the same effect, then the study or studies giving rise to the highest concern shall be used to
draw a conclusion and a robust study summary shall be prepared for that study or studies and included as part of
the technical dossier. Robust summaries will be required of all key data used in the hazard assessment. If the study
or studies giving rise to the highest concern are not used, then this shall be fully justified and included as part of
the technical dossier, not only for the study being used but also for all studies reaching a higher concern than the
study being used. For substances where all available studies indicate no hazards an overall assessment of the validityof all studies should be performed.

3.2.

Step 2: Classification and Labelling

3.2.1. The appropriate classification and labelling developed in accordance with the criteria in Directive 67/548/EEC shallbe presented and justified. Where applicable Specific Concentration limits, resulting from the application of
Article 4(4) of Directive 67/548/EEC and Articles 4 to 7 of Directive 1999/45/EC, shall be presented and, if they
are not included in Annex I to Directive 67/548/EEC, justified.
3.2.2. If the information are inadequate to decide whether a substance should be classified for a particular end-point, theregistrant shall indicate and justify the action or decision he has taken as a result.

3.3.

Step 3: Identification of the PNEC

3.3.1. Based on the available information, the PNEC for each environmental sphere shall be established. The PNEC may
be calculated by applying an appropriate assessment factor to the effect values (e.g. LC50 or NOEC). An assessment
factor expresses the difference between effects values derived for a limited number of species from laboratory tests
and the PNEC for the environmental sphere (1).
3.3.2. If it is not possible to derive the PNEC, then this shall be clearly stated and fully justified.

4.

PBT AND VPVB ASSESSMENT

4.0.

Introduction

4.0.1. The objective of the PBT and vPvB assessment shall be to determine if the substance fulfils the criteria given in
Annex XIII and if so, to characterise the potential emissions of the substance. A hazard assessment in accordancewith Sections 1 and 3 of this Annex addressing all the long-term effects and the estimation of the long-term exposure of humans and the environment as carried out in accordance with Section 5 (Exposure Assessment), step 2(Exposure Estimation), cannot be carried out with sufficient reliability for substances satisfying the PBT and vPvB
criteria in Annex XIII. Therefore, a separate PBT and vPvB assessment is required.
4.0.2. The PBT and vPvB assessment shall comprise the following two steps, which shall be clearly identified as such inPart B, Section 8 of the Chemical Safety Report:
Step 1: Comparison with the Criteria.
Step 2: Emission Characterisation.
The assessment shall also be summarised in the Safety Data Sheet under heading 12.

4.1.

Step 1: Comparison with the Criteria
This part of the PBT and vPvB assessment shall entail the comparison of the available information, which is
submitted as part of the technical dossier, with the criteria given in Annex XIII and a statement of whether thesubstance fulfils or does not fulfil the criteria.
If the available information is not sufficient to decide whether the substance fulfils the criteria in Annex XIII, thenother evidence like monitoring data available for the registrant and giving rise to an equivalent level of concern
shall be considered on a case-by-case basis.

(1) In general, the more extensive the data and the longer the duration of the tests, the smaller is the degree of uncertainty and the size of theassessment factor. An assessment factor of 1 000 is typically applied to the lowest of three short term L(E)C50 values derived from species
representing different trophic levels and a factor of 10 to the lowest of three long-term NOEC values derived from species representing
different trophic levels.

L 136/77

L 136/78

EN

Official Journal of the European Union

If the technical dossier contains for one or more endpoints only information as required in Annexes VII and VIII,
the registrant shall consider information relevant for screening for P, B and T properties to decide whether further
information needs to be generated to fulfil the objective of the PBT and vPvB assessment. In case the generation offurther information is necessary and would require testing on vertebrate animals, the registrant shall submit atesting proposal. However, such further information does not need to be generated if the registrant implements orrecommends sufficient risk management measures and operational conditions that enable derogation according to
Section 3 of Annex XI from testing relevant for PBT and vPvB assessment.

4.2.

Step 2: Emission Characterisation
If the substance fulfils the criteria an emission characterisation shall be conducted comprising the relevant parts ofthe exposure assessment as described in Section 5. In particular it shall contain an estimation of the amounts ofthe substance released to the different environmental compartments during all activities carried out by the manufacturer or importer and all identified uses, and an identification of the likely routes by which humans and theenvironment are exposed to the substance.

5.

EXPOSURE ASSESSMENT

5.0.

Introduction
The objective of the exposure assessment shall be to make a quantitative or qualitative estimate of the dose/concentration of the substance to which humans and the environment are or may be exposed. The assessment shallconsider all stages of the life-cycle of the substance resulting from the manufacture and identified uses and shallcover any exposures that may relate to the hazards identified in Sections 1 to 4. The exposure assessment shallentail the following two steps, which shall be clearly identified as such in the Chemical Safety Report:
Step 1: Generation of exposure scenario(s) or the generation of relevant use and exposure categories.
Step 2: Exposure Estimation.
Where required and in accordance with Article 31, the exposure scenario shall also be included in an annex to the
Safety Data Sheet.

5.1.

Step 1: Development of exposure scenarios

5.1.1. Exposure scenarios as described in Sections 0.7 and 0.8 shall be generated. Exposure scenarios are the core of theprocess to carry out a chemical safety assessment. The chemical safety assessment process may be iterative. The
first assessment will be based on the required minimum and all available hazard information and on the exposure
estimation that corresponds to the initial assumptions about the operating conditions and risk management
measures (an initial exposure scenario). If the initial assumptions lead to a risk characterisation indicating that risks
to human health and the environment are not adequately controlled, then it is necessary to carry out an iterative
process with amendment of one or a number of factors in hazard or exposure assessment with the aim to demonstrate adequate control. The refinement of hazard assessment may require generation of additional hazard information. The refinement of exposure assessment may involve appropriate alteration of the operational conditions orrisk management measures in the exposure scenario or more precise exposure estimation. The exposure scenario,
resulting from the final iteration (a final exposure scenario), shall be included in the chemical safety report andattached to the safety data sheet in accordance with Article 31.
The final exposure scenario shall be presented under the relevant heading of the chemical safety report, andincluded in an annex to the safety data sheet, using an appropriate short title giving a brief general description of
the use, consistent with those given in Section 3.5 of Annex VI. Exposure scenarios shall cover any manufacture in
the Community and all identified uses.
In particular, an exposure scenario includes, where relevant, a description of:Operational conditions— the processes involved, including the physical form in which the substance is manufactured, processed and/or
used,— the activities of workers related to the processes and the duration and frequency of their exposure to thesubstance,— the activities of consumers and the duration and frequency of their exposure to the substance,

29.5.200729.5.2007

EN

Official Journal of the European Union— the duration and frequency of emissions of the substance to the different environmental compartments andsewage treatment systems and the dilution in the receiving environmental compartment.
Risk management measures— the risk management measures to reduce or avoid direct and indirect exposure of humans (including workers
and consumers) and the different environmental compartments to the substance,— the waste management measures to reduce or avoid exposure of humans and the environment to the substanceduring waste disposal and/or recycling.
5.1.2. Where a manufacturer, importer or downstream user applies for an application for an authorisation for a specificuse, exposure scenarios need only be developed for that use and the subsequent life-cycle steps.

5.2.

Step 2: Exposure Estimation

5.2.1. The exposure shall be estimated for each exposure scenario developed and shall be presented under the relevant
heading of the Chemical Safety Report and where required and in accordance with Article 31, summarised in anannex to the safety data sheet. The exposure estimation entails three elements: (1) emission estimation;(2) assessment of chemical fate and pathways; and (3) estimation of exposure levels.

5.2.2. The emission estimation shall consider the emissions during all relevant parts of the life-cycle of the substanceresulting from the manufacture and each of the identified uses. The life-cycle stages resulting from the manufactureof the substance cover, where relevant, the waste stage. The life-cycle stages resulting from identified uses cover,where relevant, the service-life of articles and the waste stage. The emission estimation shall be performed under
the assumption that the risk management measures and operational conditions described in the exposure scenario
have been implemented.

5.2.3. A characterisation of possible degradation, transformation, or reaction processes and an estimation of environmental distribution and fate shall be performed.

5.2.4. An estimation of the exposure levels shall be performed for all human populations (workers, consumers andhumans liable to exposure indirectly via the environment) and environmental spheres for which exposure to thesubstance is known or reasonably foreseeable. Each relevant route of human exposure (inhalation, oral, dermal andcombined through all relevant routes and sources of exposure) shall be addressed. Such estimations shall takeaccount of spatial and temporal variations in the exposure pattern. In particular, the exposure estimation shall takeaccount of:— adequately measured, representative exposure data,— any major impurities and additives in the substance,— the quantity in which the substance is produced and/or imported,— the quantity for each identified use,
— implemented or recommended risk management, including the degree of containment,— duration and frequency of exposure according to the operational conditions,— the activities of workers related to the processes and the duration and frequency of their exposure to thesubstance,— the activities of consumers and the duration and frequency of their exposure to the substance,— the duration and frequency of emissions of the substance to the different environmental compartments and the
dilution in the receiving environmental compartment,

L 136/79

L 136/80

EN

Official Journal of the European Union— the physicochemical properties of the substance,— transformation and/or degradation products,— the likely routes of exposure of and potential for absorption in humans,— the likely pathways to the environment and environmental distribution and degradation and/or transformation(see also Section 3 Step 1),— scale (geographical) of exposure,— matrix dependent release/migration of the substance.
5.2.5. Where adequately measured representative exposure data are available, special consideration shall be given to themwhen conducting the exposure assessment. Appropriate models can be used for the estimation of exposure levels.
Relevant monitoring data from substances with analogous use and exposure patterns or analogous properties canalso be considered.

6.

RISK CHARACTERISATION

6.1.

The risk characterisation shall be carried out for each exposure scenario and shall be presented under the relevant
heading of the Chemical Safety Report.

6.2.

The risk characterisation shall consider the human populations (exposed as workers, consumers or indirectly via
the environment and if relevant a combination thereof) and the environmental spheres for which exposure to thesubstance is known or reasonably foreseeable, under the assumption that the risk management measures describedin the exposure scenarios in the Section 5 have been implemented. In addition, the overall environmental risk
caused by the substance shall be reviewed by integrating the results for the overall releases, emissions and losses
from all sources to all environmental compartments.

6.3.

The risk characterisation consists of:— a comparison of the exposure of each human population known to be or likely to be exposed with the appropriate DNEL,— a comparison of the predicted environmental concentrations in each environmental sphere with the PNECs,and— an assessment of the likelihood and severity of an event occurring due to the physicochemical properties of thesubstance.

6.4.

For any exposure scenario, the risk to humans and the environment can be considered to be adequately controlled,
throughout the lifecycle of the substance that results from manufacture or identified uses, if:— the exposure levels estimated in Section 6.2 do not exceed the appropriate DNEL or the PNEC, as determinedin Sections 1 and 3, respectively, and,— the likelihood and severity of an event occurring due to the physicochemical properties of the substance as
determined in Section 2 is negligible.

6.5.

For those human effects and those environmental spheres for which it was not possible to determine a DNEL or a
PNEC, a qualitative assessment of the likelihood that effects are avoided when implementing the exposure scenario
shall be carried out.

For substances satisfying the PBT and vPvB criteria, the manufacturer or importer shall use the information as
obtained in Section 5, Step 2 when implementing on its site, and recommending for downstream users, risk
management measures which minimise exposures and emissions to humans and the environment, throughout the
lifecycle of the substance that results from manufacture or identified uses.

29.5.200729.5.2007

EN
7.

Official Journal of the European Union

CHEMICAL SAFETY REPORT FORMATThe Chemical Safety Report shall include the following headings:

CHEMICAL SAFETY REPORT FORMATPART A
1.

SUMMARY OF RISK MANAGEMENT MEASURES

2.

DECLARATION THAT RISK MANAGEMENT MEASURES ARE IMPLEMENTED

3.

DECLARATION THAT RISK MANAGEMENT MEASURES ARE COMMUNICATEDPART B

1.

IDENTITY OF THE SUBSTANCE AND PHYSICAL AND CHEMICAL PROPERTIES2.

MANUFACTURE AND USES
2.1. Manufacture
2.2. Identified uses
2.3. Uses advised against

3.

CLASSIFICATION AND LABELLING

4.

ENVIRONMENTAL FATE PROPERTIES
4.1. Degradation
4.2. Environmental distribution
4.3. Bioaccumulation
4.4. Secondary poisoning

5.

HUMAN HEALTH HAZARD ASSESSMENT
5.1.

Toxicokinetics (absorption, metabolism, distribution and elimination)

5.2.

Acute toxicity

5.3.

Irritation
5.3.1. Skin
5.3.2. Eye
5.3.3. Respiratory tract

5.4.

Corrosivity

5.5.

Sensitisation
5.5.1. Skin
5.5.2. Respiratory system

5.6.

Repeated dose toxicity

5.7.

Mutagenicity

5.8.

Carcinogenicity

5.9.

Toxicity for reproduction
5.9.1. Effects on fertility
5.9.2. Developmental toxicity

5.10. Other effects
5.11. Derivation of DNEL(s)L 136/81

L 136/82

Official Journal of the European UnionEN

CHEMICAL SAFETY REPORT FORMAT6.

HUMAN HEALTH HAZARD ASSESSMENT OF PHYSICOCHEMICAL PROPERTIES
6.1. Explosivity
6.2. Flammability
6.3. Oxidising potential

7.

ENVIRONMENTAL HAZARD ASSESSMENT
7.1. Aquatic compartment (including sediment)
7.2. Terrestrial compartment
7.3. Atmospheric compartment
7.4. Microbiological activity in sewage treatment systems

8.

PBT AND VPVB ASSESSMENT9.

EXPOSURE ASSESSMENT
9.1.

(Title of exposure scenario 1)
9.1.1. Exposure scenario
9.1.2. Exposure estimation

9.2.

(Title of exposure scenario 2)
9.2.1. Exposure scenario
9.2.2. Exposure estimation(etc.)

10. RISK CHARACTERISATION
10.1. (Title of exposure scenario 1)
10.1.1. Human health10.1.1.1. Workers
10.1.1.2. Consumers
10.1.1.3. Indirect exposure to humans via the environment
10.1.2. Environment
10.1.2.1. Aquatic compartment (including sediment)
10.1.2.2. Terrestrial compartment
10.1.2.3. Atmospheric compartment
10.1.2.4. Microbiological activity in sewage treatment systems
10.2. (Title of exposure scenario 2)
10.2.1. Human health10.2.1.1. Workers
10.2.1.2. Consumers
10.2.1.3. Indirect exposure to humans via the environment

29.5.200729.5.2007

EN

Official Journal of the European Union

CHEMICAL SAFETY REPORT FORMAT
10.2.2. Environment
10.2.2.1. Aquatic compartment (including sediment)
10.2.2.2. Terrestrial compartment
10.2.2.3. Atmospheric compartment
10.2.2.4. Microbiological activity in sewage treatment systems(etc.)
10.x. Overall exposure (combined for all relevant emission/release sources)
10.x.1. Human health (combined for all exposure routes)
10.x.1.1.
10.x.2. Environment (combined for all emission sources)
10.x.2.1.

L 136/83